Table 1.

Dose-ramped infusions of urotensin II in healthy volunteers (HV) and patients with cardiovascular disease (CVD)

Variable	Group	Baseline	Urotensin 0.1 pmol min−1	Urotensin 1.0 pmol min−1	Urotensin 10 pmol min−1	Urotensin 100 pmol min−1	Urotensin 300 pmol min−1	Significance of trend	Significance between groups
Systolic BP (mmHg)	HV	133 ± 6	127 ± 5	129 ± 6	132 ± 6	134 ± 7	137 ± 5	<0.01	0.105
	CVD	140 ± 5	140 ± 5	143 ± 5	146 ± 5	148 ± 4.6	152 ± 5	<0.0001
Diastolic BP (mmHg)	HV	71 ± 3	67 ± 4	70 ± 3	71 ± 3	73 ± 3	72 ± 4	0.180	0.650
	CVD	78 ± 5	80 ± 2	82 ± 2	82 ± 3	83 ± 3	84 ± 2	0.108
Mean arterial pressure (mmHg)	HV	91 ± 3	87 ± 2	90 ± 2	92 ± 2	94 ± 2	94 ± 3	<0.05	0.382
	CVD	99 ± 3	100 ± 3	102 ± 3	103 ± 3	105 ± 3	107 ± 3	<0.0001
Heart rate (bpm)	HV	54 ± 3	55 ± 2	55 ± 2	54 ± 2	54 ± 2	57 ± 4	0.313	0.250
	CVD	59 ± 3	58 ± 3	57 ± 2	60 ± 3	60 ± 4	62 ± 4	<0.05
Absolute FBF in infused arm (ml 100 ml−1 min−1)	HV	3.08 ± 0.31	3.02 ± 0.34	3.05 ± 0.40	3.19 ± 0.36	2.78 ± 0.31	3.13 ± 0.48	0.560	0.416
	CVD	2.56 ± 0.22	2.55 ± 0.28	2.87 ± 0.22	2.69 ± 0.20	2.77 ± 0.20	2.70 ± 0.20	0.273
Ratio (infused/control arm)	HV	1.04 ± 0.05	1.01 ± 0.04	1.09 ± 0.06	1.06 ± 0.07	1.00 ± 0.06	0.95 ± 0.03	0.236	0.164
	CVD	1.06 ± 0.06	1.10 ± 0.75	1.14 ± 0.08	1.05 ± 0.09	1.23 ± 0.15	1.16 ± 0.13	0.512
Change in FBF ratio (%)	HV		−1.8 ± 5.1	5.9 ± 5.6	2.8 ± 6.6	−2.5 ± 6.8	−7.4 ± 6.0	0.204	0.399
	CVD		2.4 ± 6.3	5.4 ± 4.7	−3.4 ± 6.2	14.6 ± 8.6	9.2 ± 9.9	0.691

Data are presented as means ± SEM. BP, blood pressure; FBF, forearm blood flow.